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Gordonia sputi  
Bacteremia
To the Editor: In November 2007, 
a 69-year-old man with fever was hos-
pitalized  at  the  Northern  Hospital  in 
Marseilles, France. He also had diabe-
tes, high blood pressure, and alcohol 
and tobacco addictions. In September 
2007, he had received a diagnosis of 
laryngeal cancer, which required 2 che-
motherapy treatments through a central 
venous catheter (CVC), the second of 
which he had received 6 days before 
his November visit. Prostatic cancer, 
diagnosed 1.5 years earlier, had been 
treated by radiotherapy. At the time of 
the November admission, he had leu-
kopenia (1.77 × 109 leukocytes/L with 
0.49 × 109 polymorphonuclear cells/L) 
and  an  elevated  C-reactive  protein 
level (151 mg/L). The patient was ad-
mitted  with  a  preliminary  diagnosis 
of  drug-induced  febrile  granulocyto-
sis;  the  origin  of  his  fever  remained 
unclear.  Blood  for  culture  was  first 
collected from a peripheral vein and 
on  the  next  day  was  collected  from 
a peripheral vein and from the CVC. 
Gram-positive rods grew in the aero-
bic bottle from the CVC sample. The 
microorganism was identified by bio-
chemical tests using API Coryne strip 
(bioMérieux,  Marcy-l’Etoile,  France) 
as Rhodococcus spp. (94% similarity). 
The day after hospital admission, the 
patient  was  empirically  treated  with 
intravenous ticarcillin-clavulanate, 5 g 
3×/day; ciprofloxacin, 200 mg 2×/day; 
and  granulocyte  colony–stimulating 
factor.  One  day  later,  fever  resolved 
and the polymorphonuclear cell count 
was within normal limits. Oral antimi-
crobial drug therapy was continued for 
1 week.
Bacterial  identification  of  the 
strain  was  performed  by  16S  rRNA 
sequencing. We obtained a 1,464-bp 
sequence,  which  was  found  to  dif-
fer at only 2 nt positions from that of 
Gordonia  sputi  (GenBank  accession 
no. X80634). We concluded that our 
patient  had  catheter-related  bacter-
emia caused by G. sputi because he 
was  immunocompromised  and  had 
a CVC. We ruled out a contaminant 
because the organism did not belong 
to the normal flora of human skin and 
because fever resolved after treatment 
with antimicrobial drugs.
The genus Gordona was first de-
scribed in 1971, for coryneform bac-
teria isolated from sputum of patients 
with  pulmonary  disease  or  from  soil 
(1). It is a member of the mycolic acid–
containing group consisting of genera 
Corynebacterium,  Dietzia,  Gordonia, 
Mycobacterium, Nocardia, Rhodococ-
cus, and Tsukamurella. The genus has 
been revised several times by rearrange-
ments with the genera Rhodococcus and 
Nocardia, and the name Gordona was 
changed to Gordonia in 1997. The ge-
nus belongs to suborder Corynebacter-
ineae within the order Actinomycetales 
and  currently  contains  27  recognized 
species; only 7 have been described in 
human disease. Species are identified 
by molecular analysis.
Gordonia spp. cause a wide spec-
trum  of  disease  in  humans  (2–10; 
Table).  Neurologic  and  vascular  in-
fections in immunocompromised and 
immunocompetent patients have been 
reported.  Cutaneous  and  respiratory 
infections, otitis externa, osteitis, and 
arthritis have reportedly occurred only 
in immunocompetent patients. Bacte-
ria have most often been isolated from 
blood samples. Bacteremia has started 
from underlying disease such as a se-
questrated lung (4) or acute cholecys-
tis (5) or has been related to coronary 
artery  surgery  (2)  and  frequently  to 
CVCs  (2,3,6).  Catheter  removal  has 
been  recommended  for  treatment  of 
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Gordonia spp. infections in children 
(6),  but  the  recommendation  varied 
for  adults.  Six  cases  of  infection  in 
children have been described (6), ap-
pearing  as  bacteremia,  ventriculitis, 
and brain abscess.
Microbiologic diagnosis of Gor-
donia  spp.  remains  difficult.  Bio-
chemical profiles can lead to incorrect 
identification  of  isolates  as  Rhodo-
coccus spp. (2,4–6,9) and sometimes 
Corynebacterium spp. (3) or Nocardia 
spp. (6). Identification at the genus and 
species levels is presently obtained by 
16S rRNA sequence comparisons.
No  recommendation  for  antimi-
crobial drug susceptibility testing has 
been unanimously approved, but these 
microorganisms seem to be susceptible 
to many antimicrobial drugs (6). Pre-
vious studies suggest a combination of 
penicillins and aminoglycosides as a 
suitable therapy for Gordonia-related 
bacteremia (3). Carbapenem or fluo-
roquinolone  in  combination  with  an 
aminoglycoside can also be used (6). 
Antimicrobial  drug  susceptibility  is 
similar to that of Rhodococcus spp., 
for which Gordonia spp. are usually 
incorrectly  identified.  However,  al-
though  vancomycin  is  often  used  to 
treat Rhodococcus spp. infections, in a 
previous study 11% of Gordonia spp. 
isolates were resistant (6). Treatment 
must  therefore  be  evaluated  specifi-
cally for each patient.
Gordonia spp. are environmental 
bacteria whose implication in human 
disease seems to be increasing. Pheno-
typic identification of bacteria includ-
ed in this genus is difficult, and they 
are often poorly identified as Rhodo-
coccus spp. or Corynebacterium spp. 
Molecular identification of Gordonia 
spp.  by  using  16S  rRNA  gene  se-
quence comparison enables their char-
acterization in human disease because 
the method is more accurate. The fact 
that these bacteria are often associated 
with medical devices highlights their 
role  as  nosocomial  agents.  Gram-
positive bacilli must, therefore, not be 
systematically considered as contami-
nants,  especially  if  associated  with 
medical devices, and should be thor-
oughly identified by molecular meth-
ods in addition to biochemical tests.
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Table.	Summary	of	clinical	reports	involving	Gordonia	spp.*	
Clinical	findings,	by	system	
Gordonia sp. Vascular Cutaneous ENT Nervous Osteoarticular Respiratory	
G. rubripertincta Bacteremia	(CVC)	
(2)
Lung
infection	(2)
G. terrae Bacteremia
(cholecystitis)	(5);
bacteremia	(CVC)	
(2);	bacteremia	
(CVC)	(6)†
Granulomatous	skin	
lesion	(2);	palpebral	
abscess	(9);
granulomatous
mastitis	(7);
mycetoma	of	the	
hand	(9)
Meningitis,	brain	
abscess	(2);
brain	abscess	
(2)†
G. bronchialis Bacteremia
(sequestrated	lung)	
(4)
Recurrent	breast	
abscess	(7)
Ventriculitis	
(intraventricular	
shunt)	(6)
Sternal	wound	
infections	(2)
G. polyisoprenivorans Endocarditis	(CVC)	
(3);†	bacteremia	
(CVC)	(3)†
G. otitidis Bacteremia	(CVC)	
(6)
Otitis externa
(6)
Bronchitis (8)
G. sputi Bacteremia	(CVC)	
(2)†;	endocarditis	
(CVC)	(2);
mediastinitis
(surgery)	(2)
G. araii Arthritis
(bioabsorbable
tapered	screw)	
(10)
*ENT,	ear,	nose,	throat;	CVC,	central	venous	catheter.	Patients	were	immunocompetent	unless	otherwise	noted.	When	infection	was	associated	with	a	
medical	device,	the	device	is	listed	in	parentheses.	
†Immunocompromised	patient.		LETTERS
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Cross-reactive  
Antibodies against  
Avian Influenza  
Virus A (H5N1)
To  the  Editor:  Intravenous  im-
munoglobulin (IVIg) is used to treat 
bacterial  and  viral  infections  in  pa-
tients with primary immunodeficiency 
disease  and  those  with  autoimmune 
and inflammatory disorders (1). IVIg 
contains  pooled  IgG  from  >1,000 
blood  donors  and  antibodies  against 
various  common  human  pathogens, 
including influenza virus A.
We tested the efficacy of commer-
cial preparations of IVIg (50 mg/mL 
of  highly  purified  immunoglobulin) 
against homosubtypic influenza virus-
es A (H1N1 and H3N2) and their cross-
reactivity against avian influenza virus 
A (H5N1). IVIg preparations  (Octag-
am; Octapharma, Vienna, Austria and 
Flebogamma;  Instituto  Grifols,  Bar-
celona,  Spain)  had  hemagglutination 
inhibition (HI) titers against subtypes 
H1N1 and H3N2 ranging from 20 to 
40. Human Immunoglobulin, pH 4.0, 
(Harbin Sequel Bio-Engineering Phar-
maceutical, Harbin, People’s Republic 
of China) had lower HI titers against 
avian influenza viruses (10 for subtype 
H3N2 and <10 for subtype H1N1). As 
expected, we did not detect antibodies 
against  hemagglutinin  (HA)  of  sub-
type H5N1 (A/open-billed/stork/Nah-
konsawan/BBD0104F/2004) in any of 
the IVIg preparations (HI titer <10).
Human influenza subtype H1N1 
shares the same neuraminidase (NA) 
subtype  (human  N1)  as  subtype 
H5N1 (avian N1). We therefore tested 
whether IVIg preparations would re-
act and inhibit NA activity of human 
and avian influenza viruses by using 
a neuraminidase inhibition (NI) assay 
(2). NI titer was defined as the recip-
rocal of the highest dilution that gave 
50% reduction compared with that of 
the virus control.
All 3 IVIg preparations inhibited 
NA  activity  of  human  N1  (NI  titer 
against  subtype  H1N1  range  258–
986) and human N2 (NI titer against 
subtype  H3N2  range  1,309–3,274). 
Enzyme  activity  of  avian  N1  (7:1 
reassortant; PR8 + NA [A/Vietnam/ 
DT-0361/2005  H5N1])  was  inhib-
ited by all IVIg preparations (NI titer 
range 143–231). These findings sup-
port the recent observation of neutral-
izing antibodies against human N1 in 
human  serum,  which  could  inhibit 
enzyme  activity  of  avian  N1  from 
subtype H5N1 (3,4). We also tested 
IVIg preparations against reverse ge-
netics subtype H5N3 virus in which 
the N3 NA was derived from H2N3 
virus  (6:1:1  reassortant;  6  internal 
genes from PR8 + HA (A/Vietnam/
DT-0361/05  H5N1)  +  NA  (A/duck/
Germany 1207 H2N3) and observed 
no effect (NI titer <10). The N3 sub-
type belongs to avian influenza NA. 
Thus, antibodies against NA in IVIg 
appear to be specific for those circu-
lating human influenza viruses (hu-
man N1 and human N2).
Unlike HA and NA, virus matrix 
2  ectodomain  (M2e)  is  highly  con-
served. Its presence on the surface of 
the viral particle makes it a potential 
target of antibody response similar to 
that for HA and NA (5,6). We assessed 
reactivity of IVIg preparations against 
a  consensus  M2e  peptide  derived 
from human influenza viruses of H1, 
H2, and H3 subtypes (MSLLTEVET-
PIRNEWGCRCNDSSD)  and  those 
derived  from  A/Hong  Kong/156/97 
H5N1  (MSLLTEVETLTRNGWGCR 
CSDSSD and A/Thailand/ SP-83/2004 
H5N1  (MSLLTEVETPTRNEWECR 
CSDSSD) by using ELISA (7). Anti-
body titer was defined as the recipro-
cal of the highest dilution that had an 
optical density of 0.5 at 414 nm in our 
assay.
Results  showed  considerable 
variation  among  IVIg  preparations, 
caused by M2e peptides derived from 
different influenza viruses (titer range 
88–23,614). Among the 3 preparations, 
Human  Immunoglobulin,  pH  4.0, 
IVIg showed the highest titers against 
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